Press Releases
Sterling Signs Deal to Produce Potential COVID-19 Drug Candidate for Moleculin
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has signed an agreement with Moleculin Biotech, Inc., to support the company’s expanded development efforts for its potential COVID-19 treatment, WP1122.
Moleculin is a clinical stage pharmaceutical company with a...
Press Releases
Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19
Cipla Limited announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of...
Clinical Trials
Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19
Glenmark Pharmaceuticals Ltd. a global research-led pharmaceutical company announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients conducted across seven clinical sites in India. The open-label randomized, multicenter clinical trial, conducted in 150...
Press Releases
DuPont Nutrition & Biosciences Announces Research Collaboration with Rutgers University
DuPont Nutrition & Biosciences (DuPont) announced a research collaboration in microbiome science with the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers University in New Jersey.
The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy...
Packaging & Labelling
DHL in collaboration with R360 is supporting the Logistics Cluster in monitoring supply chains
Deutsche Post DHL Group (DPDHL) and Resilience360 are providing the Global Logistics Cluster, which is led by the United Nations World Food Programme (WFP), access to Resilience360 (R360). R360 offers a comprehensive suite of supply chain risk management solutions....
Press Releases
Pfizer and BioNTech Announce Agreement with the UK for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the...
Press Releases
Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read